GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pure Biologics SA (WAR:PUR) » Definitions » Debt-to-Revenue

Pure Biologics (WAR:PUR) Debt-to-Revenue : N/A (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Pure Biologics Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Pure Biologics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was zł13.73 Mil. Pure Biologics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was zł0.03 Mil. Pure Biologics's annualized Revenue for the quarter that ended in Sep. 2024 was zł0.00 Mil.


Pure Biologics Debt-to-Revenue Historical Data

The historical data trend for Pure Biologics's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pure Biologics Debt-to-Revenue Chart

Pure Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial 3.03 8.75 12.26 4.32 136.19

Pure Biologics Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A 34.05 1,104.67 N/A N/A

Competitive Comparison of Pure Biologics's Debt-to-Revenue

For the Biotechnology subindustry, Pure Biologics's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pure Biologics's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pure Biologics's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Pure Biologics's Debt-to-Revenue falls into.



Pure Biologics Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Pure Biologics's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(0.086 + 12.852) / 0.095
=136.19

Pure Biologics's annualized Debt-to-Revenue for the quarter that ended in Sep. 2024 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(13.725 + 0.027) / 0
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is four times the quarterly (Sep. 2024) Revenue data.


Pure Biologics Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Pure Biologics's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Pure Biologics Business Description

Traded in Other Exchanges
N/A
Address
ul. Dunska 11, Wroclaw, POL, 54-427
Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.

Pure Biologics Headlines

No Headlines